Q: Does blinding matter in RCTs of surgical procedures? A: Depends on the endpoint JAMA Surgery

We compared placebo-controlled and open-label surgical trials to identify when the placebo effect is most powerful Rasha Al-Lamee Katie Thomas NHLI

jamanetwork.com/journals/jamas…

Amazing to see a brilliant friend and colleague Michael Foley present the #ORBITA -COSMIC trial of the coronary sinus reducer with simultaneous publication in The Lancet Rasha Al-Lamee NHLI Imperial NHS 💙 #ACC2024

thelancet.com/journals/lance…

Here we go again! Want to see if the coronary sinus reducer works in refractory angina? Watch Michael Foley present the results of the ORBITA-COSMIC in the main arena at #ACC this Monday #ORBITA Fiyyaz Ahmed-Jushuf Matthew Shun-Shin Shayna Chotai Christopher Rajkumar Florentina Simader

Exciting insights from our BSCMR Valve Consortium, presented at #CMR2024 and featured in #EHJ : In severe AS, myocardial scar detected by #whyCMR pre-operatively is linked to long-term survival post-AVR. This underscores theimportance of fibrosis for post-op risk stratification.

The ethics of sham PCI and the clinical relevance of ORBITA-2 #CardioTwitter John Mandrola, MD Rasha Al-Lamee Christopher Rajkumar ms.spr.ly/6014ieegy

The ethics of sham PCI and the clinical relevance of ORBITA-2 #CardioTwitter
ms.spr.ly/6018ieews

Listen to Drs. Christopher Rajkumar, Rasha Al-Lamee & William E. Boden discuss the AHA Late-Breaker ORBITA-2 trial on the newest episode of the #ACCEL Lite podcast.

Listen here: bit.ly/3t1ecR2 #ACCEd

Fantastic work Rasha Al-Lamee, Christopher Rajkumar for the perfect presentation and the whole ORBITA-2 team 👏🏾 An amazing achievement, reward for unbelievable hard work 🙌🏾 #Orbita2 #AHA23

My TCTMD video around ORBITA-2 with Rasha Al-Lamee and Christopher Rajkumar : 📽️tctmd.com/videos/beyond-…
💡 how representative are trial participants?
💡Does this trial mean we can offer pci upfront of anti- anginal therapy?
💡 should we change guidelines?

#AHA2023 Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

Having spent an unhealthy amount of time together making #ORBITA2 happen, I can confirm that these are the TWO smartest people on the planet Matthew Shun-Shin Rasha Al-Lamee

To find out more about the #ORBITA2 trial, come to our deep dive session at 0800 in room 103C American Heart Association Rasha Al-Lamee Dr Roxana Mehran

#AHA23 ORBITA-2 - PCI for stable angina

Luis Ortega Paz interviews 🎤 Rasha Al-Lamee and Christopher Rajkumar on the results of ORBITA-2 randomized placebo-controlled trial, which were presented at the AHA Science 2023 Congress in Philadelphia

pcronline.com/News/Whats-new…

#CardioTwitter

This is the principal question of the ORBITA-STAR trial, coming in the next year Rasha Al-Lamee NHLI

❤️‍🔥 The ORBITA2 team has arrived at #AHA23 ! Less than 24 hours till our LBCT session giving PCI the ultimate test!

Saturday 11th November 2023
Location: Main Event Hall
Philly time: 10:35 AM (GMT -5 Hrs)

#ORBITA2 #AHA23 American Heart Association NHLI NIHR Imperial BRC

Just 8 days until we present the results of the placebo-controlled #ORBITA2 trial as late breaking science at #AHA23 in Philadelphia. Join us at 10:35 ET on Saturday 11/11/23. Rasha Al-Lamee Matthew Shun-Shin Prof Darrel Francis ☺ Mk CardioFellows Great Again American Heart Association

Reviewing some #aha23 material

ORBITA-2 is going to be amazing.

What a test! If PCI doesn't prove placebo resistant here, oh my. (I bet it will, at least partially)

Here is the paper -- eurointervention.pcronline.com/article/a-doub…

Check out this table>

Congrats Rasha Al-Lamee et al

Thank you RoySocMed, Sukh Nijjer and Paz Tayal . Only possible with amazing supervisors and colleagues Rasha Al-Lamee Matthew Shun-Shin Prof Darrel Francis ☺ Mk CardioFellows Great Again Michael Foley Fiyyaz Ahmed-Jushuf

ORBITA-2 wraps up enrollment! Drs. Rasha Al-Lamee and Christopher Rajkumar walk us through the design of ORBITA-2.

As a TPD I am not allowed to comment on the strike other than to wish that everyone gets together soon and settles it amicably blah blah blah.

But they never said we can't post pictures wordlessly.

So here are two pics.

Another great day for the ORBITA team. Michael Foley has finished recruiting for his MRC-funded ORBITA-COSMIC trial of the CSR in refractory angina. Expect the results in 2024. Well done Mike and thanks to all the brilliant teams that worked so hard to make this happen